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I. IntRoductIon
DIffusIon-weIghted (DW) magnetic resonance (MR) imaging is a non-invasive functional MR imaging technique that provides 
complementary information for classic anatomical imaging sequences. 
DW imaging is a form of MR imaging focuses on the 
micromovements (random, brownian) of the water molecules inside 
voxels. The relationship between histology and diffusion is complex, 
however generally densely cellular tissues or those with cellular 
swelling exhibit lower diffusion coefficients, and thus diffusion is 
particularly useful in tumor characterization and cerebral ischemia.
The diffusion characteristics of the tissue depend on its internal 
architecture (cellular packing, nucleus/cytoplasm ratio, intracellular 
organelles, cell membranes, nature of the extracellular matrix…) and 
its perfusion (micromotion of molecules in its capillaries) [1]. 
Molecular diffusion, or brownian motion, was first formally 
described by Einstein in 1905. Le Bihan et al. applied DWI on human 
brain for the first time in 1986 [2]. DW imaging has been used since the 
1990s in central nervous system imaging, but recently the utilization 
of whole body DWI is becoming a standard application in routine 
imaging, more specifically, in the field of oncologic imaging.
II. BasIcs PhysIcs
A. What is Diffusion?
Molecular diffusion is the random movement of molecules – in 
our case water (H2O) – within tissues propelled by thermal energy. 
The motion of water protons in the extracellular compartment, the 
intravascular compartment, the interaction with cell membranes and 
intracellular water protons contribute to total diffusion.
The aim of these DW sequences is to obtain images whose contrast 
is influenced by the differences in water molecule mobility. Stejskal 
and Tanner [3] introduced the application of symmetric pair of pulsed 
gradients during the preparatory phase into the basic spin echo sequence 
that is T2 weighted. 
B. How is MR Sensitizing the Tissue for Diffusion Effects? 
Within the spin echo preparation period of an EPI sequence, two strong 
gradient pulses are played out around the 180° pulse. The first pulse 
dephases the magnetization of moving and static spins and the second 
pulse will not be able to completely undo the changes induced by the 
first gradient and rephases only static spins so that the signal experiments 
almost no changes. In contrast, moving water spins acquire non-zero 
phase dispersion, resulting in signal attenuation. Free water experiences 
the strongest signal attenuation at higher b-values (Fig. 1 & 2). 
Fig. 1 a. Illustration of physical principles used for EPI diffusion-weighted imaging. 
* Corresponding author.









This paper describes basic physics as well as clinical applications of diffusion-weighted magnetic resonance 
imaging. This is a technique that provides complementary information to conventional imaging sequences 
and it is applied in the field of oncologic imaging. This paper focuses on its specific application in head and 
neck, mainly in cancer patients, for characterization of primary tumors, and also for monitoring and predicting 
treatment response after chemotherapy or radiation therapy. Last, although diffusion-weighted imaging is shown 
to add value in several areas by being part of the multi-parametric magnetic resonance imaging approach, there 
are some unsolved challenges, which are proposed as future work.
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Fig. 1 b. Water molecules displace freely in all spatial directions, travelling 
long distances between the two gradient applications. These highly mobile 
molecules acquire phase information after the application of the first gradient, 
but due to their movement they don´t rephase completely after the application 
of the second gradient, losing signal.
Fig 2. a. Illustration of physical principles used for EPI diffusion-weighted imaging. 
Fig. 2. b. Water molecules which are in a restricted environment don´t travel 
long distances so phase changes acquired during the application of the first 
gradient will be canceled by phase changes acquired during the second 
gradient, without losing signal.
C. What does the b-value Mean?
The degree of diffusion weighting of the sequence, expressed as 
the b-factor, depends on the characteristics of the diffusion gradients: 
gradient amplitude, application time and time between the two gradients.
The b-value identifies the measurements sensitivity to diffusion 
and determines the strength and duration of the diffusion gradients. It 
combines the following physical factors into b-values and is quantified 
by the apparent diffusion coefficient (ADC) measured in s/mm² (Fig. 3).
Fig. 3. Diagram of an EPI diffusion-weighted sequence illustrating the physical 
quantities of the b-values.
b =  γ2G2δ2(Δ– δ/3)  (1)
The signal ratio diffusion-weighted to non diffusion-weighted 
signal is:
0
 =  e−γ
2G2δ2(Δ−δ/3)D =  e−bD
 (2)
• S0 – signal intensity without the diffusion weighting.
• S – diffusion-weighted signal.
• γ – gyromagnetic ratio.
• G – amplitude of the two diffusion gradient pulses.
• δ – duration of the pulses.
• Δ – time between the two pulses.
• D – diffusion coefficient is a measure of the strength (velocity) 
of diffusion in tissue. The stronger the diffusion, the greater the 
diffusion coefficient, i.e. the ADC in our in vivo case.
The stronger the gradients, the longer they are applied and the more 
spread out in time, the greater the b-factor.
D. What is the Optimum b-value?
Images obtained with the lowest b-values (0-100 sec/mm2) provide 
T2-weighted EPI image with lower signal-to-noise ratio for anatomical 
reference.  However, they included external effects due to perfusion or 
microvascularization.
In the range of clinically relevant b-values (up to approximately 
1000), the greater the b-value, the stronger the diffusion weighting and 
higher the contrast in pathogenic regions is notice.
Higher b-values may depict even more lesions, at the price of 
poor SNR due to longer TEs and increased susceptibility. Increasing 
averages, which result in longer scan times, can compensate this [4]. 
Changing the b-value immediately influences other parameters like 
minimal TE, slice thickness and FOV as well as maximum matrix at 
a given optimal bandwidth. Furthermore anisotropy of tissues, also 
influences the choice (Fig. 4).
Fig. 4. Values  b50      b500             b1000
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A. Why do most Head and Neck DWI Protocols Start with 
b-value 50 s/mm²?
The selection of a low b-value larger than zero provides suppression 
of large vessels, which makes lesions more conspicuous. The 
calculation of the tissue ADC can be more accurate when starting with 
even higher b-values like 100 or 200, to omit the contribution of flow 
and micro vascular effects. 
Low b-values more often serve as anatomical reference. The fact 
of using b-value 0 in head and neck diffusion is for a shorter period of 
acquisition or seek greater SNR.
Fig. 4 shows examples of three b-values: b 50, b 500, and 
b 1000 s/mm2.
B. Why is a Minimum of three Directions Measured for each 
high b-value? 
The sensitivity of these sequences is limited to diffusion in the 
direction of the gradients, so they must be repeated by applying 
diffusion gradients in at least 3 spatial directions, and diffusion may be 
different in all three dimensions. 
Diffusion magnitude, calculated from the 3 diffusion images thus 
obtained, minimize the influence of anisotropy, renders the image 
weighted in global diffusion (trace image). The ADC images are 
therefore different depending on the sensitizing direction. 
The ‘trace image’ displays the geometric averaging of all three 
directional measurements, resulting in trace-weighted images. It 
suppresses to some extent anisotropy information and focuses on 
differences in signal attenuation. Like the ADC map, the trace-
weighted map shows the strength of the diffusion and not its 
orientation.
Two diffusion sequences with different b-factors can be used to 
quantitatively measure the degree of molecular mobility, by calculating 
the ADC, which is represented in the form of a map, whose values (in 
s/mm²) no longer depend on T2. An ADC hyposignal thus corresponds 
to a restriction in diffusion.
C. How is the ADC Calculated? 
Having measured a set of at least 2 different b-value images (e.g., b 
0 and b 1000 s/mm²) the system calculates pixel by pixel the ADC by 
linear regression.
Signal ADC = -In (S/S0)/ b (3)
The ADC pixel values together form the ADC map. On a half 
logarithmic scale, the signal decay delivers a straight tilted line whose 
slope provides the ADC. The faster the signal decay the steeper the 
slope and the higher the ADC.
The Diffusion image (b 1000) below displays reduced diffusion as 
hyperintense (brighter pixels); in contrast the ADC map displays it as 
hypointense (darker pixels). 
D. Why should I measure three or more b-values for a DWI 
protocol when two would be enough for calculating ADC?
While two b-values are sufficient for creating an ADC image, 
the selection of three b-values (b 50, b 500, b 1000) delivers a more 
accurate calculation of the ADC values (Fig. 5).
The lower SNR of the b 1000 images introduces a higher standard 
deviation of the ADC that is partially compensated by the median value 
of b500.
Here is an example of two ADC images, the first acquired with three 
b-values and the second with two b-values (Fig. 6).
Fig. 5. Values  b50      b500             b1000
Fig. 6.  ADC 3 values de b           ADC 2 values b
E. Why do we Need ADC Images, and What does the ‘A’ in ADC 
Stand For?
Diffusion sequences are actually T2 weighted sequences, sensitized 
to diffusion by gradients. 
The contrast of the diffusion image will have both diffusion and T2 
component, which must be taken into consideration in the interpretation. 
In areas with long T2, this can simulate reduced diffusion (‘T2 Shine-
Through’ effect). Calculating a pure diffusion coefficient can eliminate 
these portions of the signal.
The ‘A’ stands for apparent because we do not measure the pure 
diffusion coefficient (D or DC). In-vivo tissues, as well as the diffusion 
processes, have superimposed a capillary pseudo diffusion and gross 
motion to which the MR measurement is also very sensitive.
F. Why are some Lesions Typically Brighter than the Background 
Head and Neck Tissue on the Higher b-value Image and Darker 
on the ADC Map?
Due to the nature of certain lesions and their missing perfusion, the 
cells swell and hinder a normal diffusion; i.e., the mean free path is 
shorter. Water molecules cannot move as far in the damaged tissue as 
in normal tissue [5]. As a result, the ADC is lower and appears darker 
than the surrounding normal tissue.
G. Which Benefit does the Calculation of an Exponential Map 
Deliver?
Diffusion imaging cannot distinguish between water molecules 
motion and different microscopic movements such as those occurring 
in the microcirculation.  Depending on the tissue composition, water 
molecule movements are different, that is the reason for measuring the 
apparent diffusion in each voxel.
The exponential map or image is calculated by dividing the maximal 
b-value diffusion-weighted image by the b0 image. Mathematically the 
exponential map displays the negative exponential of the ADC; it is a 
synthetic DW image without T2 ‘shine-through’ effect [6].
The contrast behavior is similar to the high b-value image (Fig. 7).
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Fig. 7.  A. Axial T2 with fat suppression showing a hyperintense lesion in the 
right parotid gland. B. Notice the high signal intensity of the lesion In the ADC 
map. C. and the low signal in the exponential map.
H. Why Fat Saturation is Important in Studies of Diffusion?
In most applications the diffusion gradients are integrated in echo 
planar imaging (EPI) sequences, which exhibit high signal intensity in 
areas with restricted diffusion as well as in fatty tissue.
Furthermore, the fat signal is displaced in the direction of the chemical 
shift as compared to the water signal. This makes fat saturation techniques 
necessary to identify the lesions in the diffusion-weighted images.
There are several techniques to suppress the fat signal in MRI.
For head and neck DWI protocols the fat saturation based on 
SPAIR technique (SPectral Attenuated Inversion Recovery) is a good 
compromise between acquisition time, SNR and artifacts homogeneity 
and STIR (Short Tau Inversion Recovery, another fat saturation 
technique) provides a more homogeneous fat saturation, free of artifacts.
I. Why DWI in Head and Neck Imaging is so Sensitive to Artifacts? 
The most common artifacts are those related with imaging distortion 
due to the field inhomogeneity and to the differences in magnetic 
susceptibility from the anatomical tissues that compound this region; 
besides the presence of air-tissue interfaces, metal implants, dental 
amalgams or implants common in this area.
Another source of artifacts is related with movements, either 
voluntary or involuntary, such as breathing or coughing. The 
collaboration of the patient is mandatory to obtain high quality as well 
as the short as possible acquisition times.
J. High-resolution DWI, RESOLVE
Single-shot echo-planar imaging (EPI) is well established as the 
method of choice for clinical, diffusion-weighted imaging with MRI 
because of its low sensitivity to the motion-induced phase errors that 
occur during diffusion sensitization of the MR signal.
However, the method is prone to artifacts due to susceptibility 
changes at tissue interfaces and has a limited spatial resolution.
RESOLVE (multi-shot EPI sequence) is the combination of readout 
segmented EPI and parallel imaging can be used to address these 
issues by generating high-resolution, diffusion-weighted images with a 
significant reduction in susceptibility artifact compared with the single-
shot case. The technique uses data from a 2D navigator acquisition 
to perform a nonlinear phase correction and to control the real-time 
reacquisition of unusable data that cannot be corrected (Fig. 8).
K. Which new DWI Features are Introduced with Software for 
Siemens? 
There is a new ‘body diffusion’ application card with many new 
applications [7] :
• diffusion scheme monopolar/bipolar
• start ADC calculation for b > = …
• exponential ADC; no T2 shine-through
• invert gray scale (“PET-like” image) (Fig. 9).
• calculated image of artificial b-values plus (Fig. 9).
• choice of dynamic field correction
• improved fat saturation schemes
Fig. 9. B1000                 Calculated image artificial b1400   Invert gray scale
L. Image Evaluation
DWI analysis is usually qualitative, evaluating the signal intensity 
of the images obtained with high b-values as well as the correlation 
with the ADC map. This analysis can also be quantitative calculating 
the ADC values, placing a ROI (region of interest) on the ADC map 
sequence and recording the mean value in that ROI.  A value of 
1000 intensity points is to be interpreted as 1 x 10-3 mm2/s.  There 
are more complex methods such as parametric response maps that 
allow segmenting a tumor by providing better information about the 
intratumoral heterogeneity.
I. clInIcal aPPlIcatIons
The variation in motion and redistribution of water molecules 
between tissue compartments that is reflected in DW Imaging and ADC 
values helps to differentiate disease processes [5] and to characterize 
tissues, providing complementary information to conventional 
structural MR imaging [8].
At our institution most of the studies for imaging head and neck 
pathology are performed in a 1.5 Tesla MR scanner (Avanto Siemens, 
Erlangen, Germany), using EPI-DW sequences with 3 different b 
values (0, 500 and 1000 s/mm2).
It is important not to use a different MR scanner or change the 
imaging protocol during a patient follow up, as ADC values may 
differ significantly between MRI systems and sequences. In fact, ADC 
measurements obtained by one person and in the same MR imaging 
system, protocol, and sequence are reproducible and independent of 
time.
In head and neck region, anatomical structures such as the lymph 
nodes, tonsillar tissue, spinal cord and nerve roots are associated 
with non-pathological restricted diffusion probably due to their high 
cellularity or highly packed internal structure [9]. Variable diffusion 
is usually observed within submandibular and parotid glands. The 
spinal cord and tonsillar tissue are the structures with the lowest ADC 
variability and therefore should serve as reference tissue for head and Fig. 8. RESOLVE sequence.
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neck region studies. This is especially relevant evaluating treatment 
response of a tumor as they can be used for comparison.
DWI in head and neck, mainly in cancer patients, is indicated 
for tissue characterization of primary tumors and nodal metastases, 
prediction and monitoring of treatment response after chemotherapy or 
radiation therapy, and differentiation of radiation changes and residual 
or recurrent disease [10].
A. Characterization of Primary Tumors 
Head and neck cancers account for the sixth most common type of 
cancer worldwide, causing significant morbidity and mortality, being 
tobacco and alcohol consumption important risk factors. Differentiation 
of malignant head and neck tumors from benign lesions and accurate 
definite diagnosis is essential for treatment planning as well as for 
prognosis of malignant tumors.
The most relevant reports found that the mean ADC values of benign 
solid tumors were higher than those observed in malignant tumors, as 
a result of their histopathological differences. 
In general, malignant tumors with hypercellularity, enlarged nuclei, 
and a reduced extracellular matrix, have a smaller diffusion space of 
water protons hence reducing ADC values [11]. A threshold ADC value 
of 1.22 x 10-3 mm2/s provided an accuracy of 86% sensitivity, 84% 
specificity and 91% for predicting malignancy [12-14].
Furthermore, due to differences in the internal architecture of each 
lesion, variability in ADC values was reported within each group of 
tumor (benign or malignant) [12]. (Fig. 10 & 11). 
Fig. 10. Benign mixed tumour (BMT) in the superficial lobe of the right 
parotid gland. A. Axial T2-WI: high-signal round lesion. B. In DW b 1000 is 
hyperintense. C. On ADC map it does not show restrict diffusion, high signal 
intensity (1.98 × 10−3 mm2/sec). The BMT (which contains myxoid tissue) 
has the highest ADC values of all salivary gland neoplasms, commonly in 
keeping with benign nature.
Fig. 11. Malignant tumor of the right parotid gland. A. Axial T2-WI showing a 
heterogeneous, mostly hyperintense, lesion. B. On DW b1000 is hyperintense. 
C. On ADC map has low signal intensity (0.952 × 10−3 mm2/sec) consistent 
with restricted diffusion.
In fact, among squamous cell carcinomas (SCC), those showing 
highly or moderately differentiated histological type present higher 
ADC values, than poorly differentiated SCC [13-14]. This may be 
explained by the presence of liquefactive necrosis in the highly 
differentiated type.
DWI and ADC values can help to discriminate between SCC and 
non-Hodgkin Lymphoma; pathologic differences between these two 
tumors, such as the greater cellularity in lymphomas lead to a different 
behavior in this sequence. Usually lymphomas present greater diffusion 
restriction and hence lower ADC values [15-16] . The reported mean 
ADC for lymphoma is fairly consistent, in the range of 0.64 to 0.66 x 
10-3 mm2/sec [14, 16]. Distinguishing between SCC and lymphoma is 
important to optimize the treatment of these patients. Usually SCCs 
require complex surgeries with extensive resections and reconstructions, 
alone or combined with radiation therapy and/or chemotherapy, and 
lymphomas are usually treated with radio-chemotherapy.
Salivary gland tumors are a rare condition, accounting for less 
than 3% of all head and neck cancers [17]. The salivary gland tumors 
display a wide spectrum of histologic features tumors are composed 
of distinctive tissues (tumor cells, myxomatous tissues, lymphoid 
tissues, necrosis, and cysts). Conventional MRI has limited utility in 
differentiation of salivary gland tumors [18, 19]; on the other hand 
DWI is demonstrated to be very sensitive to biophysical abnormalities 
within the tumor. Preoperative prediction of tumor malignancy 
is clinically very important, because this information strongly 
influences the surgical plan. The most common benign salivary gland 
tumors are pleomorphic adenomas and Warthin tumors. In general, 
pleomorphic adenomas have highest ADC values due to the cystic 
or myxomatous component that characterized them, while Warthin 
tumors have lowest ADC values in keeping with the presence of 
lymphoid tissue [20] (Fig.  12).
Fig. 12. Warthin tumour (lymphomatous adenoma) in the left parotid gland. 
A. A smoothly marginated  mass, low to intermediate signal in coronal T2-WI 
MR. B. It is hyperintense on DWI (b 1000 sec/mm2) (arrow). C. On ADC map 
it shows low signal intensity (0.71 × 10−3 mm2/sec) (arrow), compatible with 
restricted diffusion. See the difference with the contralateral tumor in the right 
parotid gland,  which was a benign mixed tumour (BMT). 
The ADC maps for malignant salivary gland tumors (such as 
mucoepidermoid carcinomas) demonstrate relatively homogeneous 
areas of low ADC values (that represent cell proliferation), in contrast 
to other salivary gland tumors, for example lymphomas arising in 
the salivary glands, that are associated to extremely low ADC values 
(because of the presence of lymphoma cells) [15].
Anyway, in some cases, there is considerable overlap of ADC 
values, and DWI alone may not be sufficient to discriminate between 
benign and malignant salivary gland tumors [21, 22].
B. Evaluation of Lymph Nodes
The presence of cervical lymph node metastases is the most 
important prognostic factor in head and neck squamous cell carcinomas 
as this worsens the treatment outcome. Pretreatment staging is crucial 
in the management of head and neck cancer, and it has been considered 
one of the most important aspects in the selection of treatment options. 
Differentiation between inflammatory and metastatic 
lymphadenopathy is often challenging with conventional imaging [23]. 
Also, morphologic and size criteria in MRI are not enough for the 
assessment of lymph node metastases. 
DW imaging can help to detect cervical lymph node metastases, 
and to differentiate between benign and malignant enlarged lymph 
nodes. The general consensus appears to be that ADCs of malignant 
lymph nodes are significantly lower than those of normal lymph nodes 
[13, 23, 24].  Threshold ADC values (1.0-1.38x10-3mm2/s) have been 
reported to differentiate between malignant and benign lymph nodes 
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[13, 23, 25]. De Bondt et al reported a threshold, when ADC is lower 
than 1.0×10−3 mm2/s this was the strongest independent predictor of 
presence of metastasis (Fig.  13).
Fig. 13. Metastatic lymph nodes from nasopharyngeal carcinoma. A. Abnormal 
lymph nodes in bilateral submandibular regions (arrows) show intermediate 
signal intensity in coronal T1-WI and B. in fat saturations axial T2-WI. C. 
These nodes are hyperintense on DWI (b value 1000 sec/mm2) (arrows). D. On 
ADC map they show low signal intensity (from 0.64 × 10−3 mm2/sec to 0.86 × 
10−3 mm2/sec) (arrows), compatible with restricted diffusion. 
DWI can be better in differentiating between malignant and 
benign lymph nodes when abnormal lymph nodes show significantly 
different diffusion characteristics to normal lymph nodes within the 
same patient, as it is easy to compare. Despite the promising potential 
of DWI in detection of small malignant lymph nodes, low in-plane 
resolution of ADC maps and the presence of image artifacts can 
impact negatively on specificity and reproducibility of findings. For 
this reason, DWI should always be interpreted in conjunction with 
other MRI sequences to improve diagnostic accuracy [10]. Nowadays, 
depicting small metastatic lymph nodes (<4 mm) and lymph nodes with 
micrometastases that are below the resolution of currently available 
morphologic MR and DW images, remains challenging. 
C. Monitoring and Prediction of Treatment Response after 
Chemotherapy or Radiation Therapy
The prognosis of patients with SCC of the head and neck remains 
poor despite aggressive therapeutic regimens and technological 
advances in surgery [26]. DWI is a noninvasive imaging biomarker to 
predict tumor response and one of the greatest potential benefits of DW 
imaging lies in the identification of the group of patients who could 
respond or fail to respond to therapy. Furthermore this technique could 
detect disease before clinical signs or symptoms are evident. 
As DWI evaluates the motion of water molecules within intracellular 
and extracellular spaces, it reflects biological changes in tumor 
microenvironment, and therefore changes in ADC may imply changes 
in tumor composition.
There are published data that suggest the change in ADC over the 
course of treatment may indeed be a predictor of outcome [27-29], and 
could be use in monitoring treatment response.  A treatment-induced 
increase in ADC during therapy for head and neck squamous cell 
carcinoma has been confirmed in several studies, and results suggest 
that tumors that show a lower increase or even a decrease in ADC are 
more likely to fail treatment [24, 28, 30, 31, 32] (Fig. 14 & 15). 
Vandencaveye and colleagues reported ADC changes before 
pretreatment studies and 3 weeks after chemo or radiotherapy allows 
early assessment of treatment response. This allows early assessment 
of treatment response.  The ADC showed a PPV of 89% and a NPV of 
100% for primary lesions and a PPV of 70% and a NPV of 96% for 
lymph nodes33.
Fig. 14. Oropharyngeal carcinoma. A. A focal area of abnormal signal intensity 
in the base of the tongue and right tonsil (arrow) in axial T2-WI is seen. B. It is 
hyperintense onDWI (b value 1000 sec/mm2) (arrow). C. On ADC map it shows 
low signal intensity (values not shown) (arrow), compatible with restricted 
diffusion. In this case, the restricted-diffusion lesion most likely corresponds to 
malignancy.
Fig. 15. Oropharyngeal carcinoma. Same patient from Fig. 14, imaging after 
treatment (chemotherapy and radiation therapy). A. There is a significant 
decrease in the size of the focal area of abnormal signal intensity in the base 
of the tongue and right tonsil (arrow) in axial T2-WI. B. This area is no longer 
hyperintense on DWI B 1000 sec/mm2 (arrow). C. On ADC map it shows 
high signal intensity (2.02 × 10−3 mm2/sec) (arrow), i.e., there is no longer 
restriction of diffusion. A partial remission (partial response to the treatment) in 
MRI involves not only morphological improvement (T1-WI, T2-WI) but also 
complete or partial resolution of restricted diffusion in lesions with this feature.
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These findings could lead to stop ineffective treatments and to avoid 
delays in starting alternative and maybe more effective therapies.
It could also be important to develop prognostic imaging markers 
that can accurately predict treatment response before therapy. These 
imaging biomarkers may help in stratifying patients into those who 
would benefit from chemo-radiation therapy from those who would 
not. DWI studies of HNSCC have suggested that ADC can be used as 
a potential marker for prediction of treatment response and long-term 
survival [28, 32, 34]. These results are consistent with the hypothesis 
that a high pretreatment ADC value may be indicative of micronecrosis 
and, consequently, of hypoxia-mediated increased resistance to 
treatment and poor prognosis in these patients [35]. 
Kim and cols reported that the mean ADC of responders increases 
significantly after one week and it increases until the end of treatment. 
Values were found to be higher in complete responders than in partial 
responders [30].
This technique potentially could help in the detection of responder 
or not responder patients.
D. Residual or Recurrent Disease
Chemotherapy or radiation therapy changes and recurrent neck 
tumor have similar CT and MR appearance and are difficult to 
differentiate. Anatomical distortion due to surgery and the presence 
of edema and necrosis after chemo-radiation therapy may difficult the 
interpretation of the findings [36].
FDG-PET/CT may help to detect recurrent SCC [37], but inflammatory 
changes within the first 4 months following radiotherapy is an important 
confounding factor, even biopsies performed after radiotherapy to 
identify residual/recurrent disease are often equivocal [38]. 
Qualitative DW imaging analysis after treatment may be helpful and 
is most of the times is performed by means of visual assessment of 
signal intensity on DW images [39]. 
Post-therapeutic changes induced by radio or chemotherapy can 
be visualized as high, or sometimes also low, signal intensity on 
high-b-value images but generally show high signal intensity on the 
corresponding ADC map, as compared with tumors [10]. 
Recurrent head and neck SCCs are seen as soft-tissue masses with 
high FDG uptake in PET-CT, moderately high T2 signal intensity, and 
moderate to high contrast enhancement. At DW imaging, recurrent tumor 
shows restricted diffusion with low ADCs (most often <1.3 × 10−3 mm2/
sec) [28, 33, 39], which allows differentiation from benign radiation 
therapy–induced changes (ADC >1.6–1.8 × 10−3 mm2/sec) [13, 40]. 
Although ADCs often allow differentiation between tumor and 
inflammation, reported ADC thresholds differ from one series to 
another because of variable technical parameters used by various 
investigators [33, 39, 41]. For example, Vandecaveye et al [33] reported 
a high sensitivity (94.6%), specificity (95.9%) and accuracy (95.5%) 
for DWI to distinguish between tumoral and nontumoral tissue. The 
ΔADC showed a PPV of 89% and an NPV of 100% for primary lesions 
and a PPV of 70% and an NPV of 96% for lymph nodes. They also 
found that DWI yielded fewer false positives in comparison with CT 
or PET for both residual primary tumor and lymph node metastases. 
As there may be some overlap between ADCs measured in recurrent 
tumors and those in radiation therapy–induced inflammatory tissue, 
DW imaging findings must be correlated with morphologic MR 
imaging findings.
II. what aBout the futuRe?
DWI has been shown to add value in several areas by being part of 
the multi-parametric MRI approach, even though quantitative values 
tend to overlap. 
Investigations into the clinical applications are still at an early stage. 
A challenge that DWI faces is standardization of imaging protocols 
allowing for better comparisons across studies, getting higher spatial 
resolution for better tumor delineation, to depict smaller lesions, to 
reduce susceptibility artifacts and acquisition times.
The improvement of other (nonEPI) techniques, less sensitive to 
artifacts, such as halfFourier single-shot turbo spin-echo (HASTE), 
the split acquisition of fast spin-echo signals (SPLICE), PROLLELER, 
or BLADE could lead into a better approach to this difficult area. To 
achieve field homogeneity, both 1.5 Tesla and 3 Tesla, allowing better 
fat suppression could also be helpful. 
There are new applications in this field: diffusion scheme 
monopolar/bipolar, start ADC calculation for b >, exponential ADC; 
no T2 shine-through, invert gray scale (“PET-like” image) calculated 
image of artificial b-values plus, choice of dynamic field correction, 
improved fat saturation scheme.
Moreover, to develop methods to analyze ADC maps more 
accurately will be essential as well as the standardization of the 
technique acquisition and post processing methods that would allow 
setting thresholds and integrating them in clinical settings.
Finally, it will be crucial to correlate DWI with morphology on MRI 
and other functional techniques, such as Perfusion MRI, Dynamic Contrast 
Enhanced (DCE) Imaging and PET to reach a better clinical approach.
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